378 related articles for article (PubMed ID: 19762091)
21. P-glycoprotein (ABCB1) modulates collateral sensitivity of a multidrug resistant cell line to verapamil.
Laberge RM; Ambadipudi R; Georges E
Arch Biochem Biophys; 2009 Nov; 491(1-2):53-60. PubMed ID: 19772851
[TBL] [Abstract][Full Text] [Related]
22. Sensitization of ABCB1 overexpressing cells to chemotherapeutic agents by FG020326 via binding to ABCB1 and inhibiting its function.
Dai CL; Liang YJ; Chen LM; Zhang X; Deng WJ; Su XD; Shi Z; Wu CP; Ashby CR; Akiyama S; Ambudkar SV; Chen ZS; Fu LW
Biochem Pharmacol; 2009 Aug; 78(4):355-64. PubMed ID: 19410561
[TBL] [Abstract][Full Text] [Related]
23. Selective toxicity of NSC73306 in MDR1-positive cells as a new strategy to circumvent multidrug resistance in cancer.
Ludwig JA; Szakács G; Martin SE; Chu BF; Cardarelli C; Sauna ZE; Caplen NJ; Fales HM; Ambudkar SV; Weinstein JN; Gottesman MM
Cancer Res; 2006 May; 66(9):4808-15. PubMed ID: 16651436
[TBL] [Abstract][Full Text] [Related]
24. Zhankuic Acids A, B and C from
Teng YN; Wang YH; Wu TS; Hung HY; Hung CC
Biomolecules; 2019 Nov; 9(12):. PubMed ID: 31766413
[No Abstract] [Full Text] [Related]
25. Survivin transcription is associated with P-glycoprotein/MDR1 overexpression in the multidrug resistance of MCF-7 breast cancer cells.
Liu F; Liu S; He S; Xie Z; Zu X; Jiang Y
Oncol Rep; 2010 May; 23(5):1469-75. PubMed ID: 20372866
[TBL] [Abstract][Full Text] [Related]
26. Cabazitaxel is more active than first-generation taxanes in ABCB1(+) cell lines due to its reduced affinity for P-glycoprotein.
Duran GE; Derdau V; Weitz D; Philippe N; Blankenstein J; Atzrodt J; Sémiond D; Gianolio DA; Macé S; Sikic BI
Cancer Chemother Pharmacol; 2018 Jun; 81(6):1095-1103. PubMed ID: 29675746
[TBL] [Abstract][Full Text] [Related]
27. Doxorubicin-resistant variants of human prostate cancer cell lines DU 145, PC-3, PPC-1, and TSU-PR1: characterization of biochemical determinants of antineoplastic drug sensitivity.
David-Beabes GL; Overman MJ; Petrofski JA; Campbell PA; de Marzo AM; Nelson WG
Int J Oncol; 2000 Dec; 17(6):1077-86. PubMed ID: 11078791
[TBL] [Abstract][Full Text] [Related]
28. P-glycoprotein inhibition as a therapeutic approach for overcoming multidrug resistance in cancer: current status and future perspectives.
Binkhathlan Z; Lavasanifar A
Curr Cancer Drug Targets; 2013 Mar; 13(3):326-46. PubMed ID: 23369096
[TBL] [Abstract][Full Text] [Related]
29. Reversing agents for ATP-binding cassette (ABC) transporters: application in modulating multidrug resistance (MDR).
Lee CH
Curr Med Chem Anticancer Agents; 2004 Jan; 4(1):43-52. PubMed ID: 14754411
[TBL] [Abstract][Full Text] [Related]
30. Knockdown of the Wnt receptor Frizzled-1 (FZD1) reduces MDR1/P-glycoprotein expression in multidrug resistant leukemic cells and inhibits leukemic cell proliferation.
Wang YH; Imai Y; Shiseki M; Tanaka J; Motoji T
Leuk Res; 2018 Apr; 67():99-108. PubMed ID: 29482174
[TBL] [Abstract][Full Text] [Related]
31. Impact of BCRP/MXR, MRP1 and MDR1/P-Glycoprotein on thermoresistant variants of atypical and classical multidrug resistant cancer cells.
Stein U; Lage H; Jordan A; Walther W; Bates SE; Litman T; Hohenberger P; Dietel M
Int J Cancer; 2002 Feb; 97(6):751-60. PubMed ID: 11857350
[TBL] [Abstract][Full Text] [Related]
32. Prolonged inhibition of P-glycoprotein after exposure to chemotherapeutics increases cell mortality in multidrug resistant cultured cancer cells.
Nanayakkara AK; Vogel PD; Wise JG
PLoS One; 2019; 14(6):e0217940. PubMed ID: 31173617
[TBL] [Abstract][Full Text] [Related]
33. Tenulin and isotenulin inhibit P-glycoprotein function and overcome multidrug resistance in cancer cells.
Chang YT; Wang CCN; Wang JY; Lee TE; Cheng YY; Morris-Natschke SL; Lee KH; Hung CC
Phytomedicine; 2019 Feb; 53():252-262. PubMed ID: 30668405
[TBL] [Abstract][Full Text] [Related]
34. Folic Acid-Modified Nanoerythrocyte for Codelivery of Paclitaxel and Tariquidar to Overcome Breast Cancer Multidrug Resistance.
Zhong P; Chen X; Guo R; Chen X; Chen Z; Wei C; Li Y; Wang W; Zhou Y; Qin L
Mol Pharm; 2020 Apr; 17(4):1114-1126. PubMed ID: 32176509
[TBL] [Abstract][Full Text] [Related]
35. Exploiting the metabolic energy demands of drug efflux pumps provides a strategy to overcome multidrug resistance in cancer.
Gao X; Aguanno D; Board M; Callaghan R
Biochim Biophys Acta Gen Subj; 2021 Aug; 1865(8):129915. PubMed ID: 33965440
[TBL] [Abstract][Full Text] [Related]
36. Effect of endogenous multidrug resistance 1 and P-glycoprotein expression on anticancer drug resistance in colon cancer cell lines.
Washio I; Nakanishi T; Ishiguro N; Bister B; Tamai I
Biopharm Drug Dispos; 2019 Jan; 40(1):32-43. PubMed ID: 30556139
[TBL] [Abstract][Full Text] [Related]
37. Nanotherapeutics approaches to overcome P-glycoprotein-mediated multi-drug resistance in cancer.
Halder J; Pradhan D; Kar B; Ghosh G; Rath G
Nanomedicine; 2022 Feb; 40():102494. PubMed ID: 34775061
[TBL] [Abstract][Full Text] [Related]
38. Sequential gene expression of P-glycoprotein (P-gp), multidrug resistance-associated protein (MRP) and lung resistance protein: functional activity of P-gp and MRP present in the doxorubicin-resistant human K562 cell lines.
Grandjean F; Brémaud L; Verdier M; Robert J; Ratinaud MH
Anticancer Drugs; 2001 Mar; 12(3):247-58. PubMed ID: 11290872
[TBL] [Abstract][Full Text] [Related]
39. Multidrug resistance: retrospect and prospects in anti-cancer drug treatment.
Pérez-Tomás R
Curr Med Chem; 2006; 13(16):1859-76. PubMed ID: 16842198
[TBL] [Abstract][Full Text] [Related]
40. Improvement of conventional anti-cancer drugs as new tools against multidrug resistant tumors.
Dallavalle S; Dobričić V; Lazzarato L; Gazzano E; Machuqueiro M; Pajeva I; Tsakovska I; Zidar N; Fruttero R
Drug Resist Updat; 2020 May; 50():100682. PubMed ID: 32087558
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
